Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 5/20 | 0.49 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523349 | 0.84 | CASR (0.65) | CASRALDH1A1LTA4HALOX12MEN1 | |
| SCHEMBL10168515 | 0.81 | CASR (0.50) | CASRALDH1A1MAPTLTA4H | |
| SCHEMBL30406248 | 0.81 | MEN1 (0.62) | HTTLTA4HNPC1MEN1KMT2A | |
| SCHEMBL12327074 | 0.79 | CASR (1.00) | CASRALDH1A1MAPTHTTKMO | |
| SCHEMBL25760388 | 0.79 | CASR (1.00) | CASRALDH1A1MAPTHTTKMO | |
| SCHEMBL9562940 | 0.77 | LTA4H (0.73) | LTA4HPOLBCYP1A2CYP2C9 | |
| SCHEMBL6004434 | 0.77 | LTA4H (0.53) | CASRLTA4HMEN1KMT2AL3MBTL1 | |
| SCHEMBL176843 | 0.77 | LTA4H (0.53) | CASRLTA4HMEN1KMT2AL3MBTL1 | |
| SCHEMBL6006561 | 0.76 | LTA4H (0.59) | CASRALDH1A1MAPTLTA4HNPC1 | |
| Hydrochloric Acid SCHEMBL9320200 | 0.76 | ALDH1A1 (0.58) | CASRALDH1A1MAPTHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9174932-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9000208-B2 | Glutamate derivatives or salts thereof | AJINOMOTO CO., INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8877739-B2 | Prophylactic agent or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140303122-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8796485-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2554165-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | Ajinomoto Co., Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| EP-2551262-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | Ajinomoto Co., Inc. (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20110251418-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2345636-A1 | CASR AGONIST | Ajinomoto Co., Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | CASR, GIPR, GRPR | CASR 1/4885ALDH1A1 2603/4885MAPT 2352/4885 |
| US-20140303122-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885ALDH1A1 2705/4885MAPT 3790/4885 |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | GPR119, GIPR, CASR | CASR 3/4885ALDH1A1 2335/4885MAPT 4605/4885 |
| US-20110251418-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885ALDH1A1 2705/4885MAPT 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.